Jon Lenn, PhD, Chief Scientific Officer, MedPharm, has direct responsibility for the company’s global scientific operations. Since joining in 2015, he has led MedPharm’s development of cutting-edge performance models for assessing penetration and activity of clients’ products targeted towards key biochemical pathways. He has played a critical role in MedPharm’s growth as well as the development and success of the Durham, NC, US, facility.

He has more than 15 years’ experience in developing dermatological projects with Connetics, which was acquired by Stiefel itself subsequently acquired by GSK, and has been directly involved with the development and approval of eight products.


Dr Lenn received his PhD on the topical delivery of macromolecules from the University of Reading, UK.

More contributions